Merck KGaA (OTCMKTS:MKKGY – Get Free Report) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Tuesday, Zacks reports.
Separately, UBS Group lowered Merck KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th. Six analysts have rated the stock with a Hold rating. According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.
View Our Latest Stock Analysis on Merck KGaA
Merck KGaA Trading Up 0.3%
Shares of MKKGY stock opened at $33.84 on Tuesday. The firm has a market cap of $21.87 billion, a P/E ratio of 17.39, a PEG ratio of 2.92 and a beta of 0.92. Merck KGaA has a 1-year low of $23.73 and a 1-year high of $34.19. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.69 and a quick ratio of 1.09. The firm’s 50-day simple moving average is $31.71 and its 200-day simple moving average is $30.07.
About Merck KGaA
Merck KGaA is a German science and technology company headquartered in Darmstadt. Founded in 1668, it traces its origins to a pharmacy established by the Merck family and has grown into a global business serving customers in healthcare, research and industry. It is separate from the U.S.-based Merck & Co. The company operates through three main businesses. Its Healthcare division develops and markets prescription medicines, including treatments in areas such as oncology, neurology and fertility.
Read More
- Five stocks we like better than Merck KGaA
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
